Pharmaoverseas takes a significant step toward realizing its vision of providing the best service to patients in Egypt by announcing a strategic partnership with Novo Nordisk, a global leader in diabetes treatment.

The collaboration strengthens Pharmaoverseas’ position as the first pharmaceutical distributor in Egypt.

The agreement aims to better meet the needs of diabetes patients by distributing Novo Nordisk’s products throughout Egypt through Pharmaoverseas’ extensive distribution network, ensuring precise and high-quality delivery of medications to pharmacists.

Novo Nordisk is recognized as a global leader in healthcare and diabetes care, known for its commitment to research and development, The company has developed many innovative treatments for chronic diseases and is dedicated to making its operations more sustainable and environmentally friendly.

In this context, Dr. Mahab Gazzarin, Chairman of Pharmaoverseas, expressed his delight at the new partnership with Novo Nordisk. He explained that this partnership aligns with Pharmaoverseas’ ongoing efforts to strengthen its presence in the Egyptian market and enhance its services to pharmacists, maintaining its position as the pharmaceutical distribution Leader in Egypt.

This step reflects Pharmaoverseas’ commitment to providing the best range of products and delivering medications to pharmacists in a manner that upholds the highest standards of good storage practices (GSP, and secure Pharmaceutical Distribution services